The role of basal metabolic and volumetric 18F-FDG PET/CT 18 parameters and their changes in predicting pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy

[ X ]

Tarih

2022

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Hellenic Soc Nuclear Medicine

Erişim Hakkı

info:eu-repo/semantics/closedAccess

Özet

Objective: The aim of this study is to investigate the roles of pre-and post treatment quantitative fluorine-18-fluorodeoxyglucose ( F-FDG) positron emission tomography/computed tomography (PET/CT) para-18 meters including maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and their rate of change in predicting pathological complete response (pCR) in patients with local and locally advanced invasive breast cancer receiving neoadjuvant chemotherapy (NAC). Subjects and Methods: Ninety-eight patients who received NAC after being diagnosed with local and locally advanced invasive breast cancer between January 2017 and September 2021 were retrospectively included in our study. Molecular subtypes of all patients were determined. Maximum SUV, MTV, TLG, percent change in SUVmax (ASUVmax), AMTV, and ATLG obtained from PET/CT scans performed before and after NAC were calculated. The cut-off, area under curve (AUC), sensitivity, and specificity values of these parameters in predicting pCR were calculated using receiver operating characteristic (ROC) curves. Results: ATMTV (cut-off 94.01%, AUC: 0.846), ATTLG (cut-off 97.36%, AUC: 0.870), B2MTV (cut-off < 1.75, AUC: 0.764), B2TLG (cut-off < 2.11, AUC: 0.764), B2SUVmax (cut-off < 1.58, AUC: 0.767), ABMTV (cut-off 93.67%, AUC: 0.851), ABTLG (cut-off 97.22%, AUC: 0.870), ABSUVmax (cut-off 84.99%, AUC: 0.846) calculated using ROC curves were found to significantly predict pCR with high sensitivity and specificity. Conclusion: We concluded that meta-bolic and volumetric PET/CT parameters, the rates of their change, and metabolic res-ponse during NAC may be important variables in predicting pCR in patients with breast cancer.

Açıklama

Anahtar Kelimeler

Neoadjuvant Chemotherapy, Pathological Complete Response, F-18-Fdg- Pet/Ct

Kaynak

Hellenic Journal of Nuclear Medicine

WoS Q Değeri

Q4

Scopus Q Değeri

Cilt

25

Sayı

3

Künye